Your browser doesn't support javascript.
loading
Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2).
Witter, David J; Harrington, Paul; Wilson, Kevin J; Chenard, Melissa; Fleming, Judith C; Haines, Brian; Kral, Astrid M; Secrist, J Paul; Miller, Thomas A.
Afiliação
  • Witter DJ; Department of Drug Design and Optimization-Medicinal Chemistry, Merck Research Laboratories, 33 Avenue Louis Pasteur, Boston, MA 02115, USA. David_Witter@Merck.com
Bioorg Med Chem Lett ; 18(2): 726-31, 2008 Jan 15.
Article em En | MEDLINE | ID: mdl-18060775
ABSTRACT
A class of biaryl benzamides was identified and optimized as selective HDAC1&2 inhibitors (SHI-12). These agents exhibit selectivity over class II HDACs 4-7, as well as class I HDACs 3 and 8; providing examples of selective HDAC inhibitors for the HDAC isoforms most closely associated with cancer. The hypothesis for the increased selectivity is the binding of a pendant aromatic group in the internal cavity of the HDAC1&2 enzymes. SAR development based on an initial lead led to a series of potent and selective inhibitors with reduced off-target activity and tumor growth inhibition activity in a HCT-116 xenograft model.
Assuntos
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteínas Repressoras / Inibidores Enzimáticos / Inibidores de Histona Desacetilases Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: Bioorg Med Chem Lett Assunto da revista: BIOQUIMICA / QUIMICA Ano de publicação: 2008 Tipo de documento: Article País de afiliação: Estados Unidos
Buscar no Google
Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteínas Repressoras / Inibidores Enzimáticos / Inibidores de Histona Desacetilases Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: Bioorg Med Chem Lett Assunto da revista: BIOQUIMICA / QUIMICA Ano de publicação: 2008 Tipo de documento: Article País de afiliação: Estados Unidos